ACR-368

DRUG3 trials

Sponsors

Acrivon Therapeutics Inc., Acrivon Therapeutics, H. Lee Moffitt Cancer Center and Research Institute

Conditions

Endometrial AdenocarcinomaEndometrial cancerHead and Neck Squamous Cell Carcinoma

Phase 2

A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma

RecruitingNCT05548296

Acrivon TherapeuticsEndometrial Adenocarcinoma

Start: 2022-08-29End: 2027-04-30Target: 353Updated: 2026-03-24

A Phase II Study of ACR-368 and Low Dose Gemcitabine in R/M HNSCC

RecruitingNCT06597565

H. Lee Moffitt Cancer Center and Research InstituteHead and Neck Squamous Cell Carcinoma

Start: 2024-09-25End: 2028-08-23Target: 43Updated: 2025-10-20

A Phase 2 Study of ACR-368 Therapy in Subjects with Endometrial Cancer

Not yet recruitingCTIS2025-524542-10-00

Acrivon Therapeutics Inc.Endometrial cancer

Target: 36Updated: 2026-03-24

Related Papers

A phase II study of ACR-368 and low dose gemcitabine combination therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.

Journal of Clinical Oncology2025-05-28

The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trial

Nature Communications2024-03-3032 citations

Abstract 4749: Acrivon predictive precision proteomics (AP3) uncovers mechanism of resistance to ACR-368, a clinical-stage CHK1/2 inhibitor, and identifies rational combination treatment

Cancer Research2024-03-22

Abstract C002: Identification of biomarkers predictive of sensitivity to the CHK1/2 inhibitor ACR-368 using high-resolution phosphoproteomics and development of an ACR-368-tailored patient responder identification 3-marker test, ACR-368 OncoSignature

Molecular Cancer Therapeutics2023-12-01

Abstract B012: Validation of the OncoSignature assay, an ACR-368-tailored response-predictive quantitative multiplexed immunofluorescent assay for prediction of sensitivity to the CHK1/2 inhibitor ACR-368 in individual patients with cancer

Molecular Cancer Therapeutics2023-12-01